DNTH Filings — Dianthus Therapeutics, Inc. - FilingSpy
DNTH
Dianthus Therapeutics, Inc.
A clinical-stage biotech developing antibody therapies for severe autoimmune diseases, Dianthus Therapeutics is built around its lead candidate, claseprubart, a selective C1s inhibitor designed for convenient subcutaneous self-injection and now in late-stage trials for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A second candidate, DNTH212, targets immune signals behind these diseases. The company holds worldwide development and commercial rights to its medicines outside Greater China.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -532.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.